Navigation Links
Jules Musing to Lead Business Development Effort
Date:12/7/2011

NEWARK, Del., Dec. 7, 2011 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) today announced that Jules A. Musing, an iBio Director, will assume a role as a Managing Director of the Company for at least the next six months in order to accelerate the Company's business development activity.  Mr. Musing, formerly a Senior Executive at Johnson & Johnson, joined iBio's Board of Directors in June of 2011.  In the course of his career in the Pharmaceutical and Biotechnology Industry, Mr. Musing has been President and Managing Director for Johnson & Johnson, Janssen Pharmaceutica, and Ares Serono companies.  At Johnson & Johnson, Mr. Musing was also responsible for worldwide licensing and acquisition of pharmaceutical and biotechnology products and technologies and the establishment of strategic alliances.  His activities included the establishment of new scientific and product collaborations in various therapeutic areas, the negotiation of licensing and alliance agreements with biotechnology and pharmaceutical companies worldwide, and the partnering, spin-out and out-licensing of company pharmaceutical and biotechnology assets.

In his role as an iBio Managing Director, Mr. Musing will focus on the Company's business development and licensing activities, including direct dealings with third parties and development of human and material resources to enlarge the Company's business development capacity.

"Jules will help us expand our business development capability rapidly to deal with the product candidates already developed on our platform and those we expect in the next few months," said Robert B. Kay, iBio's Chairman and CEO.  "We expect Jules' experience as a deal maker and his access to senior management in potential users of our technologies to lead to important business opportunities for us in a variety of U.S. and international markets. We are most fortunate to have his participation during this stage of our growth."

About iBio, Inc.iBio develops and offers product applications of its iBioLaunch™ platform, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The technology has been applied successfully to proteins difficult or impossible to produce with other methods, as well as proteins representative of most important classes of biologic pharmaceuticals. Advantages of the iBioLaunch platform over other systems include enablement of rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more; product entry that is unconstrained by traditional process patents; and significantly lower capital and operating costs for comparable production. Further information is available at: www.ibioinc.com.

Forward-Looking StatementsStatements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.

 Contacts: 

  

 

 Corporate:

Investor:

  

 

 Robert Erwin, President

Douglas Beck, CFO

 iBio, Inc.

iBio, Inc.

 302-355-2335

302-355-0923

 rerwin@ibioinc.com

ir@ibioinc.com

  


'/>"/>

SOURCE iBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kronos Announces First Quarter Business Update and Financial Results
2. Growth Achieved in Spherixs Health Sciences Consulting Business
3. ImaRx Therapeutics Transitions Business Strategy
4. Argonauta Communications Certified as Women-Owned Business by the Womens Business Enterprise National Council (WBENC)
5. New Pharma Business Model Increases Pressure on Staff Communicating Trial Data
6. Small Business Innovation Research Program Awards Grant to Biomoda
7. American Dairy Provides Business Update
8. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
9. Pharmos Issues Business Update on Dextofisopam Trial and Financing
10. One Call Now Offers Notification Service at NO CHARGE for Governments, Schools, Businesses, Religious Organizations and Others in Response to Swine Flu Outbreak
11. Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... , Jan. 20, 2017  Faruqi & Faruqi, LLP, ... Inc. ("KemPharm" or the "Company") (NASDAQ: KMPH ) ... Company and certain officers and directors and underwriters of the ... seek the role of lead plaintiff. The lawsuit ... District Court for Johnson County on ...
(Date:1/20/2017)... , Jan 20, 2017 Research ... Stability Testing Market Trends, Opportunities, and Future" report to their ... This ... sizing, emerging trends, and technologies, and provides a snapshot of the ... is 2015 and forecasts are provided from 2016 to 2020. The ...
(Date:1/19/2017)... Germany Cataract Surgery Devices ... report, "Germany Cataract Surgery Devices Market Outlook to 2022", ... Devices market. The report provides value, in millions of ... within market segements - Phacoemulsification Equipment and Ophthalmic Viscoelastic ... and distribution shares data for each of these market ...
Breaking Medicine Technology:
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... "ProRandom is a set of camera tools ... create dynamic looks in Final Cut Pro X," said Christina Austin - CEO of Pixel ... to two layers of text with video footage. ProRandom works by using a virtual ...
(Date:1/23/2017)... ... ... “The Inn at the Mill”: a story of love and redemption, hope and uncertainty ... and content. , “The Inn at the Mill” is the creation of published author, ... and is now living in Berks County on Crow Hill. The inn, the ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Some Infallible Characteristics of ... Father. “Some Infallible Characteristics of Christ” is the creation of published author, Rev. Dr. ... Baptist Church for thirteen years, a preacher for over nineteen, a pastor for over ...
(Date:1/22/2017)... , ... January 22, 2017 , ... "Photo Cloud allows ... create a beautiful 3D slideshow with complete ease," said Christina Austin - CEO of ... to place in the FCPX timeline. Presets include scenes with one, three, ...
(Date:1/21/2017)... ... January 21, 2017 , ... "ProDOF is the perfect set of tools for video ... subject in a scene," said Christina Austin - CEO of Pixel Film Studios. , ... Easily create the illusion of a DSLR racking focus from one area into the next. ...
Breaking Medicine News(10 mins):